FES PET is routinely utilized to guide management in patients with ER+ breast carcinoma by noninvasively providing whole body interrogation of bioavailable ER+ disease, prognosticating response to estrogen targeted therapies, and helping distinguish ER+ breast carcinoma metastases from other malignancies when present. Here, ESR1 is linked to breast carcinoma.